OpERA

African Medicines Agency (AMA): Origins, Evolution and Future Prospects

This poster was presented at DIA 2026 and examines the development of the African Medicines Agency (AMA), tracing its evolution from the African Medicines Regulatory Harmonisation (AMRH) Programme to its [...]

2026-08-03T11:06:26+00:00August 6th, 2026|Tags: , , |

Testing the UMBRA benefit-risk tool in a South African agency

Objectives Regulators must balance medicine benefits and risks while ensuring consistency, transparency, and efficiency in decision-making and the aim of this study was to assess UMBRA’s impact on SAHPRA [...]

2026-02-05T14:42:56+00:00July 2nd, 2025|Tags: , , , |

Assessing Good Review Practices at the FDA Ghana

Objectives To identify the current perspective of the FDA Ghana in the implementation of Good Review Practices, provide a baseline on the knowledge, attitudes, practices, as well as identify [...]

2026-02-05T14:43:08+00:00July 2nd, 2025|Tags: , , |
Go to Top